AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial

Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied by at least one fully active nucleoside reverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ying, Keene, Claire, Griesel, Rulan, Sayed, Kaneez, Gcwabe, Zimasa, Jackson, Amanda, Ngwenya, Olina, Schutz, Charlotte, Goliath, Rene, Cassidy, Tali, Goemaere, Eric, Hill, Andrew, Maartens, Gary, Meintjes, Graeme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372637/
https://www.ncbi.nlm.nih.gov/pubmed/36017341
http://dx.doi.org/10.12688/wellcomeopenres.16597.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372637/
https://www.ncbi.nlm.nih.gov/pubmed/36017341
http://dx.doi.org/10.12688/wellcomeopenres.16597.1

Ejemplares similares